Background:
Nicotinamide mononucleotide adenylyltransferase (NMNAT) (EC2.7.7.1) is a central enzyme in NAD+ biosynthesis, transferring the adenylyl moiety of ATP to nicotinamide mononucleotide (NMN) or nicotinic acid mononucleotide (NaMN) resulting in the formation of NAD+ or NaAD+ and the release of pyrophosphate. As this reaction is reversible, the enzyme may in principle be used to form ATP and NMN from NAD+ and pyrophosphate.
NMNAT2 is predominantly expressed in human pancreas, insulinoma as well as in the brain, especially in the cerebrum, cerebellum, occipital lobe, frontal lobe, temporal lobe and putamen. Immunofluorescence microscopy localized endogenous NMNAT2 to the Golgi apparatus in human cell line. Endogenous NMNAT2 seem to be a labile axon survival factor, because specific depletion of NMNAT2 is sufficient to induce Wallerian-like degeneration of uninjured axons which endogenous NMNAT1 and NMNAT3 cannot prevent. Thus endogenous NMNAT2 represents an exciting new therapeutic target for axonal disorders.
Shipping Temp. (°C):
Dry Ice
Related Products:
*CycLex NAMPT Colorimetric Assay Kit: Cat# CY-1251;*CycLex NMNAT Colorimetric Assay kit: Cat# CY-1252;*CycLex NAD+/NADH Colorimetric Assay Kit: Cat# CY-1253;*NAMPT (Nicotinamide Phosphoribosyltransferase): Cat# CY-E1251
*NMNAT1 (Nicotinamide Mononucleotide Adenylyltransferase 1): Cat# CY-E1252-1;*NMNAT2 (Nicotinamide Mononucleotide Adenylyltransferase 1): Cat# CY-E1252-2;*CycLex SIRT1/Sir2 Deacetylase Fluorometric Assay Kit: Cat# CY-1151
*CycLex SIRT2 Deacetylase Fluorometric Assay Kit: Cat# CY-1152;*CycLex SIRT3 Deacetylase Fluorometric Assay Kit: Cat# CY-1153
*CycLex SIRT6 Deacetylase Fluorometric Assay Kit: Cat# CY-1156;*NAD(+)-Dependent Deacetylase SIRT1: Cat# CY-E1151
*NAD(+)-Dependent Deacetylase SIRT2: Cat# CY-E1152;
*NAD(+)-Dependent Deacetylase SIRT3: Cat# CY-E1153
*NAD(+)-Dependent Deacetylase SIRT6: Cat# CY-E1156
References:
1. Raffaelli, N.; Sorci, L.; Amici, A.; Emanuelli, M.; Mazzola, F.; Magni, G. : Biochem. Biophys. Res. Commun. 297: 835-840, 2002.
2. Seki, N.; Ohira, M.; Nagase, T.; Ishikawa, K.; Miyajima, N.; Nakajima, D.; Nomura, N.; Ohara, O. : DNA Res. 4: 345-349, 1997.
3. Yalowitz, J. A.; Xiao, S.; Biju, M. P.; Antony, A. C.; Cummings, O. W.; Deeg, M. A.; Jayaram, H. N. : Biochem. J. 377: 317-326, 2004.
4. Zhang, X.; Kurnasov, O. V.; Karthikeyan, S.; Grishin, N. V.; Osterman, A. L.; Zhang, H. : J. Biol. Chem. 278: 13503-13511, 2003.
5. J Gilley and MP Coleman: PLoS Biol. 8: e1000300, 2010
Intended Use:
For Research use only. Not for use in diagnostic procedure.
Background:
Lectin-like oxidized LDL receptor-1 (LOX-1), a 52-kD type II transmembrane receptor for oxidized low-density lipoproteins (ox-LDL) belonging to the C-type lectin family is present primarily on endothelial cells (1). Accumulating evidences indicate that oxLDL uptake through this receptor induces endothelial dysfunction. oxLDL binding to endothelial LOX-1 generates superoxide anions, decreases nitric oxide production, and activates NF-kB (2, 3). Endothelial LOX-1 expression is induced by various pro-inflammatory cytokines, such as TNF-alpha (4) and TGF-beta (5) as well as by pro-atherogenic factors, such as oxLDL and advanced glycation end products in vitro (6). This receptor is expressed in the aortas of hypertensive, diabetic, and hyperlipidemic animals (6-8) and is upregulated in early human atherosclerotic lesions (9). These results suggest that LOX-1 may be expressed locally and play important roles in atherogenesis by internalizing and degrading oxLDL and in inflammatory responses in vivo. LOX-1 can be cleaved from the cell surface and released as soluble LOX-1 (sLOX-1), and elevated sLOX-1 levels may be indicative of atherosclerotic plaque instability (10).
Related Products:
CD5L /Sp? ELISA Kit: Cat# CY-8080;S100A12/EN-RAGE ELISA Kit: Cat# CY-8058;Anti-Human Sp?/CD5L (Lymphocyte antigen CD5-like): Cat# CY-P1036
References:
1. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. (1997) Nature 386: 73-77
2. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, Rigoni A, Pastorino AM, Lo Cascio V, Sawamura T. (2000) J Biol Chem. 275: 12633ヨ12638.
3. Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M, Pastorino AM, Lo Cascio U, Sawamura T. (2001) J Biol Chem. 276: 13750ヨ13755.
4. Kume N, Murase T, Moriwaki H, Aoyama T, Sawamura T, Masaki T, Kita T. (1998) Circ Res. 83: 322ヨ327.
5. Draude G and Lorenz R. L. (2000) Am J Physiol Heart Circ Physiol. 278: H1042ヨH1048.
6. Nagase M, Hirose S, Sawamura T, Masaki T, Fujita T. (1997) Biochem Biophys Res Commun. 237: 496ヨ498.
7. Chen M, Nagase M, Fujita T, Narumiya S, Masaki T, Sawamura T. (2001) Biochem Biophys Res Commun. 287: 962ヨ968.
8. Chen M, Kakutani M, Minami M, Kataoka H, Kume N, Narumiya S, Kita T, Sawamura T. (2000) Arterioscler Thromb Vasc Biol. 20: 1107ヨ1115.
9. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T, Sawamura T, Masaki T, Hashimoto N, Kita T. (1999) Circulation 99: 3110 ヨ3117.
10. Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, Tanaka M, Ueda A, Kominami G, Kambara H, Kimura T, Kita T. (2005) Circulation 112: 812-818.
Intended Use:
For Research use only. Not for use in diagnostic procedure.
Background:
Nicotinamide adenine dinucleotide (NAD+) as well as nicotinamide adenine dinucleotide phosphate (NADP+) is an important cofactor found in cells. NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH. It has been reported that NAD+ metabolism regulates important biological effects including life span. NAD+, through poly-ADP-ribosyl polymerase (PARP), mono-ADP- ribosyltransferase (ARTs) and recently characterized sirtuin enzymes, exerts potential biological effects. These enzymes modify proteins to regulate their function via ADP-ribosylation or deacetylation in the presence of NAD+. These enzymes are involved in several pathways including apoptosis, DNA repair, senescence and endocrine signaling, suggesting that either the enzymes could be an important therapeutical target for cancer, diabetes atherosclerosis and so on.
The traditional NAD+/NADH and NADP+/NADPH assays are done by monitoring of NADH or NADPH absorption at 340 nm. This method suffers low sensitivity and high interference since the assay is done in the UV range that requires expensive quartz microplate. CycLex NAD+/NADH Colorimetric Assay Kit employs an enzyme cycling reaction, which significantly increases detection sensitivity, and provides a convenient method for sensitive detection of NAD+, NADH and their ratio.
Shipping Temp. (°C):
Dry Ice
Related Products:
PM054 anti--Tubulin (polyclonal)
References:
1. Ziegenhorn J, Senn M, Bucher T. (1976) Molar absorptivities of beta-NADH and beta-NADPH. Clin
Chem. 22: 151.
2. Matsumura, H. and Miyachi S (1980) Cycling assay for nicotinamide adenine dinucleotides. Methods Enzymol. 69: 465-470.
3. Zerez CR, Lee SJ, Tanaka KR (1987) Spectrophotometric determination of oxidized and reduced pyridine nucleotides in erythrocytes using a single extraction procedure. Anal Biochem. 164: 367-73
4. Zhao, Z, Hu, X and Ross CW (1987). Comparison of Tissue Preparation Methods for Assay of Nicotinamide Coenzymes. Plant Physiol. 84: 987-988.
5 Umemura, K and Kimura, H (2005) Determination of oxidized and reduced nicotinamide adenine dinucleotide in cell monolayers using a single extraction procedure and a spectrophotometric assay. Anal Biochem. 338: 131-5.
6. Hasmann, M and Schemainda, I (2003) FK866, a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis. Cancer Research 63: 7436-7442, 2003
7.Vilcheze, C et al. (2005). Altered NADH/NAD+ Ratio Mediates Coresistance to Isoniazid and Ethionamide in Mycobacteria. Antimicrobial Agents and Chemotherapy. 49: 708-720.
8. Kimura N, Fukuwatari T, Sasaki R, Shibata K. (2006) Comparison of metabolic fates of nicotinamide, NAD+ and NADH administered orally and intraperitoneally; characterization of oral NADH. J Nutr Sci Vitaminol. (Tokyo) 52: 142.
9. O'Donnell JM, et al. (2004) Limited transfer of cytosolic NADH into mitochondria at high cardiac workload. Am J Physiol Heart Circ Physiol. 286: H2237.
10. Richard A. et al. (2008) Characterization of NAD Uptake in Mammalian Cells J. Biol. Chem. 283: 6367-6374.
11. Rongvaux, A et al. (2008) Nicotinamide Phosphoribosyl Transferase/Pre-B Cell Colony-Enhancing Factor/Visfatin Is Required for Lymphocyte Development and Cellular Resistance to Genotoxic Stress J. Immunol. 181: 4685-4695
12. Pogrebniak, A et al. (2006) Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res. 11: 313-21.
Intended Use:
For Research use only. Not for use in diagnostic procedure.
Background:
The Golgi apparatus is a eukaryotic organelle, which is mainly devoted to processing the proteins synthesized in the endoplasmic reticulum (ER). GM130 is a member of the golgin family of coiled-coil proteins that localizes predominantly to the cis-Golgi. GM130 might participate in ER-Golgi traffic.
Product Type:
Primary Antibody
References:
Diao, A., et al., J. Biol. Chem. 283, 6957-6967 (2008)
Alvarez, C., et al., J. Biol. Chem. 276, 2693-2700 (2001)
Intended Use:
For Research use only. Not for use in diagnostic procedure.
Background:
The early endosome is a cellular compartment inside eukaryotic cells. It is receiving endocytosed material and sorting them for vesicular transport to late endosomes and lysosomes or for recycling to the plasma membrane. EEA1 (Early Endosome Antigen1) is a 170 kDa coiled-coil protein, which is required for vesicular transport of proteins through early endosomes. It binds membrane lipids through its FYVE domain.
Product Type:
Primary Antibody
References:
Gaullier, J. M., et al., J. Biol. Chem. 275, 24595-24600 (2000)
Mu, F. T., et al., J. Biol. Chem. 270, 13503-13511 (1995)
Intended Use:
For Research use only. Not for use in diagnostic procedure.
Background:
The endoplasmic reticulum (ER) is a eukaryotic organelle, which serves many general functions, including the facilitation of protein folding. Calnexin is a 90 kDa integral membrane protein of the ER. Calnexin is one of the chaperone proteins, which play a major role in the quality control of the ER by the retention of incorrectly folded proteins.
Product Type:
Primary Antibody
Intended Use:
For Research use only. Not for use in diagnostic procedure.
Background:
The KDEL (lys-asp-glu-leu) sequence is most common endoplasmic reticulum (ER) retention signal. The ER resident proteins, which should be located in the ER, have this retention motif, and this retention is mediated by KDEL receptor. This antibody can specifically detect GRP78 (78 kDa protein) and GRP94 (94 kDa protein) including a KDEL sequence by WB.
Product Type:
Primary Antibody
References:
Pelham, H. R., EMBO J. 7, 913-918 (1988)
Munro, S., and Pelham, H. R., Cell 48, 899-907 (1987)
Intended Use:
For Research use only. Not for use in diagnostic procedure.
Background:
HRP-DirecT is a series of HRP conjugated primary antibodies developed by MBL.
HRP-DirecT Series products don’t need secondary antibodies. That brings the following advantages:
â‘ Total incubation time is cut in half.
The reaction with the secondary antibody becomes unnecessary. In the shaking method, reaction time is only 30 minutes. Spend your evening doing more important things.
Clear result
No more heavy and light chain bands in Immunoprecipitation. The HRP conjugated primary antibody will not detect your precipitating antibody. Clear result helps your research.
Usually, the secondary antibody amplifies the signal of an unconjugated primary antibody. Therefore, it is thought to be difficult to obtain a strong signal with a directly conjugated antibody. To overcome this hurdle, MBL has improved the HRP conjugation method. MBL’s HRP-DirecT Series yield strong signal with minimum background. Give it a try - the HRP-DirecT Series will not disappoint you.
Product Type:
Primary Antibody
Intended Use:
For Research use only. Not for use in diagnostic procedure.
Background:
HRP-DirecT is a series of HRP conjugated primary antibodies developed by MBL.
HRP-DirecT Series products don’t need secondary antibodies. That brings the following advantages:
â‘ Total incubation time is cut in half.
The reaction with the secondary antibody becomes unnecessary. In the shaking method, reaction time is only 30 minutes. Spend your evening doing more important things.
Clear result
No more heavy and light chain bands in Immunoprecipitation. The HRP conjugated primary antibody will not detect your precipitating antibody. Clear result helps your research.
Usually, the secondary antibody amplifies the signal of an unconjugated primary antibody. Therefore, it is thought to be difficult to obtain a strong signal with a directly conjugated antibody. To overcome this hurdle, MBL has improved the HRP conjugation method. MBL’s HRP-DirecT Series yield strong signal with minimum background. Give it a try - the HRP-DirecT Series will not disappoint you.
Product Type:
Primary Antibody
Intended Use:
For Research use only. Not for use in diagnostic procedure.
Background:
HRP-DirecT Series
HRP-DirecT is a series of HRP conjugated primary antibodies developed by MBL.
HRP-DirecT Series products don’t need secondary antibodies. That brings the following advantages:
â‘ Total incubation time is cut in half.
The reaction with the secondary antibody becomes unnecessary. In the shaking method, reaction time is only 30 minutes. Spend your evening doing more important things.
Clear result
No more heavy and light chain bands in Immunoprecipitation. The HRP conjugated primary antibody will not detect your precipitating antibody. Clear result helps your research.
Usually, the secondary antibody amplifies the signal of an unconjugated primary antibody. Therefore, it is thought to be difficult to obtain a strong signal with a directly conjugated antibody. To overcome this hurdle, MBL has improved the HRP conjugation method. MBL’s HRP-DirecT Series yield strong signal with minimum background. Give it a try - the HRP-DirecT Series will not disappoint you.
Product Type:
Primary Antibody
Intended Use:
For Research use only. Not for use in diagnostic procedure.
|